恩沃利单抗联合帕博利珠单抗对比铂类化疗±阿维鲁单抗维持一线治疗局部晚期/转移性尿路上皮癌的校正比较
本研究基于EV-302患者水平数据和JAVELIN-Bladder 100研究水平数据,通过建模校正EV-302中未进展患者接受阿维鲁单抗维持的比例,构建混合铂类化疗±阿维鲁单抗组,与观察到的EV+P组比较。结果显示EV+P较铂类化疗±阿维鲁单抗显著改善无进展生存期(HR 0.51,95%CI 0.44-0.59)和总生存期(HR 0.64,95%CI 0.49-0.86)。
要点
- EV+P较铂类化疗±阿维鲁单抗显著改善PFS(HR 0.51)和OS(HR 0.64)。
- 校正模型假设所有未进展患者均接受阿维鲁单抗维持治疗。
- 结果支持EV+P作为la/mUC一线标准治疗。
核心结论
- EV+P较铂类化疗±阿维鲁单抗在la/mUC一线治疗中提供PFS和OS获益,强化其标准治疗地位。
研究设计与样本
- 建模研究,使用EV-302患者水平数据与JAVELIN-Bladder 100研究水平数据进行比较。
- 将JB-100中阿维鲁单抗对比最佳支持治疗的HR应用于EV-302中22周一线治疗后未进展的铂类化疗亚组。
- 采用加权风险方法将未进展患者与进展患者合并,构建混合铂类化疗±阿维鲁单抗组,与观察到的EV+P组比较。
主要发现
- EV+P较铂类化疗±阿维鲁单抗改善无进展生存期(HR 0.51,95%CI 0.44-0.59)。
- EV+P较铂类化疗±阿维鲁单抗改善总生存期(HR 0.64,95%CI 0.49-0.86)。
- 敏感性分析结果一致。
临床怎么用
- 对于la/mUC一线治疗,EV+P应作为优选方案,其生存获益优于铂类化疗±阿维鲁单抗维持策略。
局限性
- 假设所有未进展患者均接受阿维鲁单抗维持治疗,可能不完全反映真实世界模式。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: First-line (1L) treatment options for locally advanced or metastatic urothelial carcinoma (la/mUC) include enfortumab vedotin plus pembrolizumab (EV+P), based on EV-302, or platinum-based chemotherapy (PBC) with avelumab maintenance for patients without progression, based on JAVELIN-Bladder 100 (JB-100). Clinicians must choose between EV+P and PBC without knowing whether patients will respond to PBC and qualify for avelumab. In EV-302, avelumab maintenance was approved after trial initiation and therefore, was potentially underutilized among patients without progression. This modeling study facilitated a true 1L comparison of EV+P versus PBC ± avelumab. METHODS: Progression-free survival and overall survival were compared using EV-302 patient-level data and JB-100 study-level data. The JB-100 hazard ratio (HR) for avelumab versus best supportive care was applied to a comparable EV-302 PBC subgroup of patients without progression after a 22-week 1L period. This replaced EV-302 data for patients without progression to reflect outcomes assuming all EV-302 patients without progression received avelumab as observed in JB-100. Using a weighted hazard approach, patients without progression were combined with EV-302 patients with progression to obtain a hybrid PBC ± avelumab arm, which was compared with observed EV+P outcomes. Weighted average HRs with 95% confidence intervals (CIs) were calculated. KEY FINDINGS AND LIMITATIONS: EV+P improved progression-free survival (HR 0.51, 95% CI 0.44-0.59) and overall survival (HR 0.64, 95% CI 0.49-0.86) versus PBC ± avelumab. Results were consistent across sensitivity analyses. Limitations include assuming all patients without progression received avelumab, which may not reflect real-world patterns. CONCLUSIONS AND CLINICAL IMPLICATIONS: EV+P provides progression-free survival and overall survival benefits over PBC ± avelumab, reinforcing its position as the 1L standard of care in patients with la/mUC.
引用
- Dillon R, Jones R, Fléchon A, et al. Adjusted Comparison of First-line Enfortumab Vedotin Plus Pembrolizumab Versus Platinum-based Chemotherapy ± Avelumab Maintenance for the Treatment of Locally Advanced/Metastatic Urothelial Carcinoma. Eur Urol Oncol. 2026. PMID: 42362438. doi:10.1016/j.euo.2026.06.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。